REGN earnings: a positive outcome, +6.2%

On July 30, 2026, Regeneron Pharmaceuticals, Inc. reached its earnings. The result was a positive outcome, and the stock moved +6.2% in the window around the event. It had already run +7.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.